Catalog No. |
TD-HY378026 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG4-nd |
Expression system |
Mammalian Cells |
Species |
Human |
Clonality |
Monoclonal |
Target |
Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2, CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L, CR-3 alpha chain, Cell surface glycoprotein MAC-1 subunit alpha, Leukocyte adhesion receptor MO1, ITGAM, CD11b, CD11 antigen-like family member B, Integrin alpha-M, CR3A, CD11B, Neutrophil adherence receptor |
Endotoxin level |
Please contact with the lab for this information. |
Purity |
>95% as determined by SDS-PAGE. |
Purification |
Protein A/G purified from cell culture supernatant. |
Accession |
P05107 & (P20701 + P11215) |
Form |
Liquid |
Storage buffer |
0.01M PBS, pH 7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names |
Bispecific, Hu23F2G, 23F2G, CAS: 339086-79-2 |
Background |
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke. |
Note |
For research use only. Not suitable for clinical or therapeutic use. |